AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces today that the brand name for the company’s drug Zeqmelit® has been registered for trademark protection in all member states of the European Union. Brand protection is of strategic importance ahead of the company’s commercialization phase. The application for trademark protection for Zeqmelit® has previously also been submitted for the American market.
"It is very gratifying that we have now received trademark protection in Europe for our oral film Zeqmelit® and associated areas of use. This means that the company's assets are protected and that we can proceed with full force to establish the medicine on the European market", says AcuCort’s CEO Jonas Jönmark.
The trademark protection in Europe is part of the trademark work that AcuCort previously started to change the name of the company's main product from ISICORT to Zeqmelit®. The trademark protection for Zeqmelit® in Europe is valid for the next 10 years, after which the company must apply for an extension.
The information was submitted for publication, through the agency of the contact person below, on January 3, 2023.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark and Norway. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.